Remdesivir and favipiravir price regulation required to safeguard patients’ interest in India: GlobalData Read more
Serum Institute of India gets DCGI nod for phase 2 and 3 human trials of Oxford vaccine candidate Read more
COVID-19 panel recommends DCGI to permit SII to conduct human trials of Oxford vaccine candidate Read more
SLAs to issue manufacture/sale licenses for AYUSH formulations only after approval from AYUSH Ministry Read more
Health ministry decides against including Itolizumab in clinical management protocols for COVID-19 Read more